FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies

Authors

Pierre Peterlin,[1,2] Joëlle Gaschet,[2] Pascal Turlure,[3] Marie-Pierre Gourin,[3] Pierre-Yves Dumas,[4] Sylvain Thepot,[5] Ana Berceanu,[6] Sophie Park,[7] Marie-Anne Hospital,[8] Thomas Cluzeau,[9] Jose-Miguel Torregrosa-Diaz,[10] Louis Drevon,[11] Rosa Sapena,[12] Fatiha Chermat,[12] Lionel Ades,[11] Sophie Dimicoli-Salazar,[4] Maxime Jullien,[1,2] Pierre Fenaux[12] and Patrice Chevallier[1,2]

[1]Clinical Hematology, Nantes University Hospital, Nantes; [2]CRCI2NA UMR INSERM 1307CNRS 6075 - Nantes Université – Angers University, Nantes; [3]Clinical Hematology, Limoges University Hospital, Limoges; [4]Clinical Hematology, Bordeaux University Hospital Haut-Lévêque, Pessac; [5]Clinical Hematology, Angers University Hospital, Angers; [6]Clinical Hematology, Besançon University Hospital, Besançon; [7]Clinical Hematology, Grenoble University Hospital, Grenoble; [8]Clinical Hematology, Institut Paoli Calmettes, Marseille; [9]Clinical Hematology, Nice University Hospital, Nice; [10]Clinical Hematology, Poitiers University Hospital, Poitiers; [11]Clinical Hematology, Saint Louis Hospital, Paris and [12]Groupe Francophone des Myélodysplasies, Paris, France

Correspondence:
P. PETERLIN - pierre.peterlin@chu-nantes.fr

https://doi.org/10.3324/haematol.2024.286025

Received: June 6, 2024.
Accepted: November 13, 2024.
Early view: November 21, 2024.

Figure legends

Supplemental figure 1. Forest plot of multivariate analysis.
sFL: soluble Flt3-ligand; FLI: sustained increase from day 1 to day 22; FLD: increase until day 15, then decrease; FLL: persistent low levels; F: female; M: male; IPSS-M: Molecular International Prognostic Scoring System; L:low; H:high;VH: very high; OR: odds ratio.

Supplemental figure 1